Influence of transplanted dose of CD56 + cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors

Bone Marrow Transplantation

Volumn 32, Issue 5, 2003, Pages 505-510

  Yamasaki, S ^a   Henzan, H ^a   Ohno, Y ^b   Yamanaka, T ^c   Iino, T ^a   Itou, Y ^a   Kuroiwa, M ^d   Maeda, M ^a   Kawano, N ^e   Kinukawa, N ^c   Miyamoto, T ^a   Nagafuji, K ^a   Shimoda, K ^a   Inaba, S ^c   Hayashi, S ^e   Taniguchi, S ^d   Shibuya, T ^d   Gondo, H ^a   Otsuka, T ^a   Harada, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d HAMANOMACHI HOSPITAL   (Japan)

^e HARASANSHIN HOSPITAL   (Japan)

Author keywords

Allogeneic peripheral blood; CD56 + cells; G CSF mobilized peripheral blood progenitor cells; Graft versus host disease; HLA identical sibling donors; Progenitor cell transplantation

Indexed keywords

BUSULFAN; CD56 ANTIGEN; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; THIOTEPA;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; CELL COMPOSITION; CELL COUNT; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOCOMPETENT CELL; INCIDENCE; LEUKEMIA; LIVING DONOR; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REGRESSION ANALYSIS; SIBLING; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD; ANTIGENS, CD56; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS;

EID: 10744225346     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704165     Document Type: Article

References (37)

1. Harada M. Allogeneic peripheral blood stem cell transplantation is coming of age. Int J Hematol 1995; 62: 1-5.
2. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
3. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98: 3186-3191.
4. Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-3691.
5. Vigorito AC, Azevedo WM, Marques JFC et al. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-1151.
6. Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380-3389.
7. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
8. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hemato-poietic cells for allogeneic transplantation. Blood 2000; 95: 3702-3709.
9. Theilgaard-Moench K, Raaschou-Jensen K, Palm H et al. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant 2001; 28: 1073-1082.
10. Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant 2000; 26: 1-16.
11. Dreger P, Haferlach T, Eckstein V et al. G-CSF-mobilized peripheral blood progenitor cells allogeneic transplantation: safety, kinetic of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-613.
12. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
13. Weaver CH, Longin K, Buckner CD et al. Lymphocyte content in peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony stimulating factor. Bone Marrow Transplant 1994; 13: 411-415.
14. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
15. Koerbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+Thy-1 dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
16. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first result of a randomized multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
17. Blaise D, Kuentz M, Fortanier C et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
18. Heldal D, Tjonnfjord G, Brinch L et al. A randomized study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129-1136.
19. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant disease: a randomized trial. Lancet 2000; 355: 1231-1237.
20. Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761-767.
21. Couban S, Simpson DR, Barnett MJ et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
22. Harada M, Nagafuji K, Fujisaki T et al. G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. J Haematother 1996; 5: 63-71.
23. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1-9.
24. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
25. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, pp 339-362.
26. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001; 28: 909-915.
27. Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
28. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990; 6: 283-289.
29. Storb R, Doney KC, Thomas ED et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982; 59: 236-246.
30. Rooney C, Wimperis J, Brenner M et al. Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol 1986; 62: 413-420.
31. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
32. Asai O, Longo D, Tian Z et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998; 101: 1835-1842.
33. Sykes M, Hoyles KA, Romick ML, Sachs DH. In vitro and in vivo analysis of bone marrow-derived CD3+, CD4-, CD8-, NK1.1+ cell lines. Cell Immunol 90; 129:478-482.
34. Lan F, Zeng D, Higuchi M et al. Predominance of NK1.1+TCRαβ+ or DX+TCRαβ+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: natural suppressor cells. J Immunol 2001; 167: 2087-2096.
35. Przepiorka D, Smith TL, Folloder J et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
36. Auffermann-Gretzinger S, Losses IS, Vayntrub TA et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002; 99: 1442-1448.
37. Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695-1700.